Target discovery Euretos Disease Atlas provides quantitative causal inference across 34,000 indications with cell-type resolution, offering a precise target scoring approach that could enhance a pharma or biotech partner’s target discovery and validation workflows.

Evidence transparency Scores are linked to primary measurements with calibrated probabilities for causal biology, clinical reach, and approval, plus explicit per-disease confidence tiers, which can support risk assessment and decision-making for external collaborations and licensing.

Single-cell focus Default cell-type resolution and integration of single-cell data (e.g., from CellxGene and Human Cell Atlas) address tissue- and cell-context targeting needs, appealing to translational research groups seeking context-rich target evaluation.

Recent milestones Recent launches and funding activity, including Euretos Perspectives and a €10.7M grant for predictive personalized hypertension treatment, signal growth, validation momentum, and potential collaboration or co-development opportunities.

Expansion potential Product enhancements such as orthologs, similar proteins, and a dedicated single-cell study viewer demonstrate a roadmap valuable to partners pursuing cross-species target translation, expanded asset evaluation, and external platform integrations.